Immune checkpoint blockade is an attractive strategy in EBV-associated NPC, given its favorable immune landscape, characterized by an abundance of tumor-infiltrating lymphocytes and high expression of PD-L1 and regulators of T-cell activation [38]. This evidence concerns the gene CD274 and neoplasm.